Related Experiment Video
Updated: Feb 5, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer
Rasmus Siersbæk1, Sanjeev Kumar1,2, Jason S Carroll1
1Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, United Kingdom.
Abstract:
Estrogen receptor α (ER) is the major driver of ∼75% of breast cancers, and multiple ER targeting drugs are routinely used clinically to treat patients with ER+ breast cancer. However, many patients relapse on these targeted therapies and ultimately develop metastatic and incurable disease, and understanding the mechanisms leading to drug resistance is consequently of utmost importance. It is now clear that, in addition to estrogens, ER function is modulated by other steroid receptors and multiple signaling pathways (e.g., growth factor and cytokine signaling), and many of these pathways affect drug resistance and patient outcome. Here, we review the mechanisms through which these pathways impact ER function and drug resistance as well as discuss the clinical implications.
Insights
Estrogen receptor alpha (ER) drives most breast cancers. Understanding how other pathways affect ER function is crucial for overcoming drug resistance in ER-positive breast cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- Estrogen receptor alpha (ER) is a primary driver in approximately 75% of breast cancers.
- Current ER-targeting therapies are standard for ER-positive breast cancer but often lead to relapse and metastatic disease.
- Mechanisms of drug resistance are critical to understand for improving patient outcomes.
Purpose of the Study:
- To review how non-estrogen signaling pathways modulate ER function.
- To explore the impact of these pathways on ER-targeted drug resistance.
- To discuss the clinical implications of these findings for breast cancer treatment.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of signaling pathways intersecting with ER.
- Synthesis of information on mechanisms of drug resistance.
Main Results:
- ER activity is modulated by various steroid receptors and signaling pathways, including growth factor and cytokine signaling.
- These pathways contribute significantly to the development of resistance to endocrine therapies.
- Understanding these interactions is key to identifying novel therapeutic strategies.
Conclusions:
- Modulation of ER function by diverse signaling pathways is a critical factor in breast cancer drug resistance.
- Targeting these intersecting pathways may offer new avenues for overcoming resistance and improving treatment efficacy.
- Further research into these mechanisms is essential for advancing ER-positive breast cancer therapy.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Internal Receptors
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Signal Sequences and Sorting Receptors
Receptor-mediated Endocytosis
G-protein Coupled Receptors

